Cryoport (CYRX) Competitors $6.70 -0.05 (-0.74%) Closing price 02/13/2025 04:00 PM EasternExtended Trading$6.87 +0.17 (+2.60%) As of 02/13/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYRX vs. NRIX, DYN, VIR, KNSA, ARDX, MRVI, XNCR, SNDX, DAWN, and ANIPShould you be buying Cryoport stock or one of its competitors? The main competitors of Cryoport include Nurix Therapeutics (NRIX), Dyne Therapeutics (DYN), Vir Biotechnology (VIR), Kiniksa Pharmaceuticals (KNSA), Ardelyx (ARDX), Maravai LifeSciences (MRVI), Xencor (XNCR), Syndax Pharmaceuticals (SNDX), Day One Biopharmaceuticals (DAWN), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Cryoport vs. Nurix Therapeutics Dyne Therapeutics Vir Biotechnology Kiniksa Pharmaceuticals Ardelyx Maravai LifeSciences Xencor Syndax Pharmaceuticals Day One Biopharmaceuticals ANI Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do insiders & institutionals have more ownership in NRIX or CYRX? 92.9% of Cryoport shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Cryoport shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, NRIX or CYRX? Cryoport has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M24.44-$193.57M-$2.89-6.08Cryoport$233.26M1.42-$99.59M-$3.38-1.98 Does the MarketBeat Community believe in NRIX or CYRX? Cryoport received 162 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 79.41% of users gave Nurix Therapeutics an outperform vote while only 65.15% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformNurix TherapeuticsOutperform Votes8179.41% Underperform Votes2120.59% CryoportOutperform Votes24365.15% Underperform Votes13034.85% Does the media refer more to NRIX or CYRX? In the previous week, Nurix Therapeutics had 2 more articles in the media than Cryoport. MarketBeat recorded 2 mentions for Nurix Therapeutics and 0 mentions for Cryoport. Nurix Therapeutics' average media sentiment score of 0.92 beat Cryoport's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Nurix Therapeutics Positive Cryoport Neutral Which has more risk & volatility, NRIX or CYRX? Nurix Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Is NRIX or CYRX more profitable? Cryoport has a net margin of -70.08% compared to Nurix Therapeutics' net margin of -354.85%. Cryoport's return on equity of -13.35% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-354.85% -53.65% -38.59% Cryoport -70.08%-13.35%-6.43% Do analysts prefer NRIX or CYRX? Nurix Therapeutics presently has a consensus target price of $31.12, indicating a potential upside of 77.11%. Cryoport has a consensus target price of $12.29, indicating a potential upside of 83.37%. Given Cryoport's higher probable upside, analysts clearly believe Cryoport is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryCryoport beats Nurix Therapeutics on 10 of the 18 factors compared between the two stocks. Get Cryoport News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoportPharmaceutical IndustryTransportation SectorNASDAQ ExchangeMarket Cap$331.18M$6.93B$306.74B$9.18BDividend YieldN/A2.90%4.36%4.00%P/E Ratio-1.989.8516.7619.43Price / Sales1.42289.0659.0777.19Price / Cash17.9275.4612.7238.87Price / Book0.715.572.105.07Net Income-$99.59M$123.72M$583.39M$222.90M7 Day Performance-4.42%-2.08%-0.54%0.37%1 Month Performance-20.14%1.11%-0.06%5.51%1 Year Performance-55.03%5.75%6.10%23.18% Cryoport Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoport2.321 of 5 stars$6.70-0.7%$12.29+83.4%-55.0%$331.18M$233.26M-1.981,170NRIXNurix Therapeutics2.313 of 5 stars$18.78-4.7%$31.12+65.7%+101.5%$1.44B$54.55M-6.59300DYNDyne Therapeutics3.5318 of 5 stars$13.93-2.0%$49.91+258.2%-39.2%$1.43BN/A-3.94100VIRVir Biotechnology4.2139 of 5 stars$9.97-4.1%$34.83+249.4%+8.2%$1.37B$86.18M-2.54580KNSAKiniksa Pharmaceuticals3.5479 of 5 stars$19.00-3.1%$36.60+92.6%-1.1%$1.36B$270.26M-134.91220Insider TradeNews CoverageARDXArdelyx3.4561 of 5 stars$5.32-0.8%$9.42+77.2%-36.1%$1.26B$124.46M-17.7590Upcoming EarningsShort Interest ↑Gap DownMRVIMaravai LifeSciences4.2613 of 5 stars$4.96+0.5%$10.28+107.5%-19.8%$1.25B$288.95M-3.02610XNCRXencor3.8636 of 5 stars$17.71-3.1%$34.88+96.9%-14.8%$1.24B$168.34M-5.56280SNDXSyndax Pharmaceuticals3.8204 of 5 stars$14.43+1.8%$36.20+150.9%-28.9%$1.24BN/A-3.99110Insider TradeDAWNDay One Biopharmaceuticals1.8191 of 5 stars$12.09-2.3%$35.86+196.6%-14.0%$1.22BN/A-11.7760ANIPANI Pharmaceuticals4.3884 of 5 stars$58.02-1.1%$77.71+34.0%+7.6%$1.22B$486.82M-105.49600 Related Companies and Tools Related Companies Nurix Therapeutics Competitors Dyne Therapeutics Competitors Vir Biotechnology Competitors Kiniksa Pharmaceuticals Competitors Ardelyx Competitors Maravai LifeSciences Competitors Xencor Competitors Syndax Pharmaceuticals Competitors Day One Biopharmaceuticals Competitors ANI Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYRX) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | SponsoredJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | Sponsored[RFK Jr CONFIRMED] But Will THIS Be His DownfallRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s #1 investment during Trump’s termWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cryoport, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cryoport With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.